PAC Partners analyst Nick Maxwell maintained a Buy rating on Austco Healthcare Limited on July 23 and set a price target of A$0.50.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nick Maxwell has given his Buy rating due to a combination of factors that highlight Austco Healthcare Limited’s strong financial position and growth potential. The company has demonstrated impressive revenue growth, achieving a record $13.2 million in June, which reflects the successful integration of G&S Technologies. This integration is expected to contribute significantly to the company’s performance in FY26, as it brings a full year of operations under Austco’s management.
Additionally, Austco Healthcare’s financial metrics are attractive, with an estimated FY26 EV/EBITDA multiple of 6x and a Price-to-earnings multiple of 12x. The company’s cash position has improved, and the increase in the Amentco earnout to $8.4 million indicates stronger than expected EBITDA performance. Furthermore, the unfilled contracted revenue has risen to $55.8 million, providing revenue visibility well into FY26. These factors, combined with a history of conservative guidance that has been met or exceeded, underpin Maxwell’s confidence in the company’s future prospects.
In another report released on July 24, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a A$0.50 price target.
AHC’s price has also changed moderately for the past six months – from A$0.320 to A$0.385, which is a 20.31% increase.